Clinical Pipeline

Learn more about our pipeline

Trials for Market Approval

Download PPT

Pre-Clinical (GLP)

FNDR-20081

Foundation for Neglected Disease Research

FNDR 20364

National Centre of Oceanic and Antarctic Research (NCAOR), Gao, India

Sanfetrinem

GlaxoSmithKline, Bill & Melinda Gates Foundation

OTB-658

Institute of Materia Medica, CAMS & PUMC

TB47

Guangzhou Institute of Respiratory Medicine Company Limited, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

GSK839

GlaxoSmithKline

MBX-4888A

Microbiotix, Inc.

Phase 1

GSK-286

GlaxoSmithKline, TB Drug Accelerator, Bill & Melinda Gates Foundation

Phase 1 Safety, Tolerability and Pharmacokinetics of GSK2556286

TBAJ-587, Diarylquinoline

TB Alliance, ERA4TB (European Regimen Accelerator for Tuberculosis), University of Auckland, Merck & Co., Inc.

TBI-223

TB Alliance, Institute of Materia Medica

TBI-223 Phase 1 MAD

BVL-GSK098

BioVersys AG, GlaxoSmithKline

Phase 1 Safety, Tolerability and Pharmacokinetics of BVL-GSK098

Macozinone (MCZ, PBTZ-169)

iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation

TBAJ-876 Diarylquinoline

TB Alliance, University of Auckland

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

TBI-166

Institute of Materia Medica, CAMS & PUMC

Phase 2

Sudapyridine (WX-081)

Shanghai Jiatan Biotech Ltd., subsidiary of Guangzhou JOYO Pharma Ltd., Shanghai, China

OPC-167832

Otsuka Pharmaceutical Development & Commercialization, Inc.

OPC-167832 Phase 1 / 2 EBA

Phase 2b/c. 4-month Regimen of OPC-167832, Delamanid and Bedaquiline for DS Pulmonary TB

Sutezolid

Sequella, Inc, TB Alliance

Sutezolid Dose-finding and Combination Evaluation (SUDOCU)

BTZ-043

University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF), European and Developing Countries Clinical Trials Partnership (EDCTP), Radboud University

BTZ-043 Multiple Ascending Dose / EBA

Rifampicin

PanACEA, EDCTP, NIAID, NIH, DHHS, USAID

ReDEFINe High-Dose RIF for Meningitis

High-Dose Rifampin

Delpazolid (LCB01-0371)

LegoChem Biosciences, Inc.

A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial of LCB01-0371.

DECODE- Delpazolid Dose-Finding and Combination Development Trial

SPR720 (Fobrepodacin)

Spero Therapeutics, LLC, Bill & Melinda Gates Medical Research Institute

GSK 3036656